Spain occupies the penultimate put in the use of insulin bombs as a treatment for diabetes with 4%.These are data collected by the Technology Group in Phenin Diabetes.With the aim of improving the patient's quality of life with type 2 diabetes mellitus (DM1), the Spanish Diabetes Federation (FEDE) has started the campaign "Diabetes does not rest, you do".
With this integrated system, the treatment of diabetes and the control of complications derived from pathology such as hypoglycemia is improved.In our country, a total of 1,235 new cases of DM1 in children under 15 are diagnosed and in this sense, 76% fail to have adequate glycemic control.
“The appearance in the last years of innovative technologies in the treatment of people with DM1, such as the integrated system of continuous subcutaneous infusion of insulin with continuous glucose monitoring and scientific evidence of their effectiveness in the improvement of metabolic control,Quality of life and clear decrease in acute complications of high sanitary cost such as hypoglycemia, is what has led Fede to mobilize and defend the rights of patients with type 1 diabetes, ”said Andoni Lorenzo, president of the Fede.
The new technology have helped the control of the DM1.For the control of the DM1 and the consequent reduction of its complications, try to achieve greater monitoring of the disease.An example of this is insulin pump, which currently has an integrated monitoring system capable of avoiding hypoglycemia in 83.1% of cases and warning the patient through an alarm system.
Despite the level of effectiveness and efficiency of therapy, new technologies have a degree of penetration in our surprisingly low country.Currently they only use insulin bomb treatment around 4% of type 1 diabetics in Spain, compared to more than 46% in Norway or 30% in Slovenia, the average of around 15% being located.
“The objective of the campaign is also to avoid, as far as possible, the inequality between autonomous communities.Currently, the different data penetration data by the Autonomous Community show the difference between Spanish regions, an inequality that increases given the non -financing of treatments, such as those that help monitor glucose levels, which causes differences in the possibility ofAccess to treatment, ”says the president of Fede.